StockData

Coya Therapeutics vs HCW Biologics

COYA and HCWB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How COYA and HCWB compare

Coya Therapeutics is the larger company, worth 48 times as much as HCW Biologics ($70.4M against $1.5M).

HCW Biologics grew revenue faster over the last twelve months (700% versus 17.6% for Coya Therapeutics).

HCW Biologics keeps more of each dollar of sales as profit, with a net margin of −83.8% compared with −643% at Coya Therapeutics.

Coya Therapeutics scores higher on the StockData Score (7 against 6 for HCW Biologics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCOYAHCWB
Size and price
Market cap$70.4M$1.5M
Share price$3.00$0.800
Change, 1 year−49.7%−94.6%
Change, 5 years–−99.9%
Beta (5Y)2.142.44
Employees8–
StockData Score
Total score7 (better)6
Valuation score13 (better)
Growth score12 (better)
Performance score01 (better)
Health score5 (better)0
Dividend score00
Valuation
P/S15.0×0.2× (better)
P/B2.1×0.2× (better)
Fair value$2.58$15.29
Margin of safety−16.2%94.8% (better)
Growth
Revenue growth (TTM)17.6%700% (better)
Revenue growth, 5Y average–−57.9%
Profitability
Gross margin–96.7%
Operating margin−675%−115% (better)
Net margin−643%−83.8% (better)
Return on equity−99.2% (better)−151%
Return on invested capital–−70.7%
Financial health
Debt / equity0.000.88 (better)
Interest coverage–−14.0×
Current ratio7.24 (better)0.06
Altman Z-score2.76 (better)−7.20
Piotroski F-score3 (better)2
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions33.1%5.6%
Held by insiders5.1%34.9%
Insider net buying, 12 months–$532K
Short interest, % of float6.3%4.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.